Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 2/20 | 0.48 |
| ▸ | MME | P08473 | 4/20 | 0.43 |
| ▸ | GRN | P28799 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5869302 | 1.00 | FOLH1 (0.50) | FOLH1CTSLCTSKACACBMME | |
| SCHEMBL30658624 | 0.83 | CTSL (0.55) | FOLH1CTSLCTSKACACBMME | |
| SCHEMBL8256203 | 0.83 | MME (0.58) | FOLH1ACACBMMEACECPA1 | |
| SCHEMBL5870045 | 0.83 | MME (0.58) | FOLH1ACACBMMEACECPA1 | |
| SCHEMBL8254444 | 0.83 | MME (0.58) | FOLH1ACACBMMEACECPA1 | |
| SCHEMBL5869782 | 0.82 | FOLH1 (0.48) | FOLH1MMEGRNSORT1ACE | |
| SCHEMBL5869787 | 0.82 | FOLH1 (0.48) | FOLH1MMEGRNSORT1ACE | |
| SCHEMBL13660693 | 0.82 | ACACB (0.50) | CTSLCTSKACACBMMEACE | |
| SCHEMBL2034306 | 0.82 | ACACB (0.50) | CTSLCTSKACACBMMEACE | |
| SCHEMBL28613611 | 0.82 | ITGB3 (0.50) | ACACBMMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082496-A1 | ACE-2 modulating compounds and methods of use thereof | ACE, ACE2, AGTR2 | FOLH1 229/4885CTSL 911/4885CTSK 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.